|
09 Apr 2019 |
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLW
|
|
08 Apr 2019 |
Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial
|
|
08 Apr 2019 |
United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint
|
|
06 Apr 2019 |
Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
|
|
05 Apr 2019 |
U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
|
|
05 Apr 2019 |
Nanobiotix announces first ever radioenhancer to receive European market approval
|
|
04 Apr 2019 |
EMA Validates Daiichi Sankyo's Marketing Authorization Application for Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating, Non-Malignant Tumor
|
|
04 Apr 2019 |
VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer
|
|
03 Apr 2019 |
Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta
|
|
03 Apr 2019 |
Amylyx Pharmaceuticals Announces First Patients Dosed in PEGASUS Phase 2 Trial of AMX0035 in Alzheimer’s Disease and Expansion of the Trial
|
|
03 Apr 2019 |
Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019
|
|
03 Apr 2019 |
Tetraphase Pharmaceuticals Presents Preclinical Data on TP-2846, a Novel Drug Candidate for Acute Myeloid Leukemia
|
|
03 Apr 2019 |
Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019
|
|
03 Apr 2019 |
Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting
|
|
02 Apr 2019 |
Roche's ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial
|
|
02 Apr 2019 |
Novel First-In-Class FLIP Inhibitors for the Treatment of Cancer
|
|
02 Apr 2019 |
TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting
|
|
02 Apr 2019 |
Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting
|
|
02 Apr 2019 |
Apollomics, Inc. Presents Positive Preclinical Data on APL-102, an oral Multi-Kinase Inhibitor with CSF-1R Activity
|
|
01 Apr 2019 |
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors
|
|
01 Apr 2019 |
BerGenBio: Bemcentinib in Combination With low-dose Chemotherapy Achieves Efficacy Endpoint in AML Patients
|
|
01 Apr 2019 |
Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine
|
|
01 Apr 2019 |
Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy
|
|
01 Apr 2019 |
Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH
|
|
01 Apr 2019 |
Shionogi Announces Submission of Cefiderocol Marketing Authorisation Application
|
